1 2	Inflammation induced epigenetic activation of bivalent genes in osteoarthritic cartilage
3	Running title: Epigenetic basis for osteoarthritis
4 5 6	Character count <b>47,760</b> Character count (including spaces) <b>56,184</b> Authors
7 8 9 10	Hao Du <sup>1,</sup> †, Yao Zhang <sup>1,</sup> †, Xi Yu <sup>1, 2</sup> , Xuanhe You <sup>1</sup> , Diwei Wu <sup>1</sup> , Zhenyu Luo <sup>1</sup> , Yongrui Cai <sup>1</sup> , Hanpeng Lu <sup>1</sup> , Zhixin Liao <sup>1</sup> , Bi-Sen Ding <sup>3</sup> , Ya Zhao <sup>4, 5</sup> , Yan Wang <sup>6, 7</sup> , Ke Xiao <sup>8</sup> , Fan Yang <sup>9</sup> , Fangji Gan <sup>10</sup> , Ning Ning <sup>1</sup> , Jiancheng Zeng <sup>1</sup> , Zongke Zhou <sup>1, *</sup> & Shishu Huang <sup>1, *</sup>
12	Affiliations
13 14	1. Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
15 16	2. Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
17 18 19	3. Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
20 21	4. Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, PR China;
22 23	5. Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yangzhou, 225001, PR China
24 25	6. College of Animal Science and Technology, Sichuan Agricultural University, Chengdu 611130, China
26 27	7. Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China
28 29	8. The lower limb department of Sichuan Province Orthopedic Hospital, the central laboratory of Sichuan Province Orthopedic Hospital, Chengdu, China
30 31 32	9. The Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences (CAS), Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.
33	10. School of Mechanical Engineering, Sichuan University, Chengdu 610065, China.
34	† These authors contributed equally to this work.
35	Corresponding author. Email: h0794062@scu.edu.cn (S.H.); zongke@126.com (Z.Z.)
36	Abstract
38	Osteoarthritis (OA) is the most prevalent joint disorder occurring with articular cartilage
39	degradation, which includes a switch from an articular to a growth-plate chondrocvte
40	phenotype. Epigenetics serves as a new therapeutic target but histone modification
41	changes in OA remain elusive. Here, we investigated the profiles of four histone
42	modifications in normal and OA chondrocytes. The repressive mark H3K27me3 was
43	significantly lost in OA, associated with up-regulated gene expression. Surprisingly,

- 44 many of these genes were occupied by both H3K27me3 and H3K4me3 in normal 45 chondrocytes, showing a poised bivalent state. These bivalent genes are deemed to be
- 46 activated during the hypertrophy of growth plate chondrocytes. Furthermore,
- 47 inflammation induced the expression of demethylase KDM6B and decreased
- 48 H3K27me3 level in OA chondrocytes, which was rescued by the KDM6B inhibitor
- 49 GSK-J4. Altogether, our results suggest an inherited bivalent epigenetic signature on
- 50developmental genes that makes articular chondrocytes prone to hypertrophy and
- 51 contribute to a promising epigenetic therapy for OA. 52
- 53 Key words: Osteoarthritis; Epigenetics; Histone modification; Chondrocyte hypertrophy

## 55 **The Paper Explained**

## 56 **Problem**

54

57 Osteoarthritis (OA) affects as much as 40% of the elderly population, representing the largest 58 cause of age-related disability. The high susceptibility to OA suggests an intrinsic and systemic

59 characteristic in articular chondrocytes that makes cartilage prone to degeneration.

### 60 **Results**

61 Epigenetic bivalent genes, which are occupied with both H3K27me3 and H3K4me3, are

62 considered to poise expression of developmental genes. Surprisingly, we reported bivalency for

63 hypertrophy related genes in normal articular chondrocytes. These bivalent genes need to be

64 activated in growth plate chondrocytes for extracellular matrix degradation and ossification, but

are left as a "bomb" for degeneration in articular chondrocytes. We further found that

inflammation induced KDM6B remove H3K27me3 to activate hypertrophy related genes thatpromote OA.

## 68 Impact

69 Our results suggest an inherited epigenetic signature that makes articular chondrocytes prone to 70 hypertrophy and ossification and contribute to a promising epigenetic therapy for OA.

## hypertrophy and ossification and contribute to a promisi

## 72 Introduction

Osteoarthritis (OA) is one of the most prevalent joint disorders that affects an estimated 300 million adults worldwide (Vos *et al*, 2017). OA is mainly characterized by chronic joint pain caused by the degradation of articular cartilage and inflammation of the synovium, which would induce age-related disability eventually. Current standard therapies for OA are limited, including pain amelioration and eventual total joint replacement (Bannuru *et al*, 2019), which do not prevent or restrain the loss of cartilage.

Up to date, many therapeutic strategies have focused on molecular pathways that are 79 80 deregulated in OA. The relevant drugs include metalloproteinase and aggrecanase inhibitors to target catabolic enzymes responsible for degradation of articular cartilage, 81 bisphosphonates and antiresorptive drugs to stabilize bone homeostasis, inducible nitric 82 83 oxide synthase (iNOS) and NF-κB inhibitors to target inflammatory pathways (Karsdal et al, 2016). These drugs, however, have had limited preclinical and clinical success 84 (Karsdal et al, 2016). One possible reason is that OA is a disease of complex pathology 85 86 which involves multiple signaling pathways and these drugs target single molecular pathway only. In fact, most risk factors of OA, including aging, obesity, trauma and 87 biomechanics, have been associated to epigenetic changes (Yang et al, 2021; Zhang et 88 89 al, 2020; Ling & Rönn, 2019). Interestingly, epigenetic regulations can act on multiple gene programs at the same time, thus having the potential to reprogram the aberrant state 90

of the cell. However, it is unknown whether epigenetic changes may play a common
 pathogenic role in the development of OA. As such, it is worth investigating epigenetic
 changes associated with OA, their potential impact on OA-associated gene expression,
 and disease pathology.

Epigenetics is defined as the changes 'on top of' (epi) the genome that influence the
transcription of genes, which mainly imply DNA methylation and various histone
modifications. Multiple studies have mapped global DNA methylation changes
associated with OA (Taylor *et al*, 2015; Reynard, 2017) and provide an attractive
therapeutic strategy (Smeriglio *et al*, 2020). Compared to DNA methylation, histone
modifications are more diverse, complex and have close interactions with the former,
providing broader therapeutic prospect (Grandi & Bhutani, 2020).

102 Histones are subject to post-translational modifications that include methylation, acetylation, phosphorylation and ubiquitylation, among others (Millán-Zambrano et al, 103 2022). Different histone modifications occupy distinct positions on the genome and 104 confer distinct active or repressive transcription effect (Hyun et al, 2017). Histone 3 105 lysine 4 trimethylation (H3K4me3) marks active transcription and is highly enriched at 106 the promoter region and transcription start site. H3K27me3 is a hallmark of 107 transcriptional repression. H3K9me3 is a well-known indicator of silenced transcription 108 and heterochromatin structure. Acetylation of H3K27 (H3K27ac) is the best-known 109 epigenetic mark for active enhancers and also enriched in highly expressed genes. 110 Promisingly, plenty of studies have revealed the involvement of histone modification 111 enzymes in cartilage development and pathology (Dudakovic et al, 2015, 2; Camilleri et 112 al, 2018, 2; Du et al, 2020, 2; Zhang et al, 2015, 3; Dai et al, 2017, 6; Monteagudo et al, 113 2017). While genome-wide changes of histone modifications associated with OA are 114 115 still unknown.

In this study, we compared the genome-wide profiles of classic histone modifications in normal and OA chondrocytes and identified a significant decrease of repressive mark H3K27me3 in OA. This H3K27me3 loss derepressed gene expression, especially of bivalent genes, which are occupied by both H3K27me3 and H3K4me3. Interestingly, these genes are deemed to be activated during developmental chondrocyte hypertrophy. Further investigation revealed that inflammation induced histone demethylase KDM6B lead to H3K27me3 loss and can be an attractive therapeutic target for OA.

123

125

#### 124 **Results**

#### The profiling of histone modifications in normal and OA chondrocytes

To gain a comprehensive view of the histone modification landscape in human articular 126 chondrocytes and identify epigenetic changes associated with OA, we performed 127 128 CUT&Tag and RNA-seq in normal and OA chondrocytes (Fig 1A). Two pairs of OA-Intact/Damaged samples were also included. OA-Intact cartilage showed slightly uneven 129 surface compared to normal cartilage, whereas OA-Damaged cartilage exhibited severe 130 131 erosion (Fig EV1A). We investigated the distribution of the activating promoter mark H3K4me3, the repressive mark H3K27me3, the promoter and enhancer mark H3K27ac, 132 and the heterochromatin mark H3K9me3. 133

We first examined the tag density of each chromatin mark in genes. H3K4me3 and 134 H3K27ac were highly enriched at the transcription start site (TSS) (Fig 1B and Fig 135 EV1B). H3K27me3 were enriched at promoters and showed broader distribution than 136 H3K4me3. Surprisingly, OA samples showed overall lower H3K27me3 compared to 137 Normal (Fig 1B). The heterochromatin mark H3K9me3 showed low tag density on gene 138 bodies in all samples. Subsequently, we used SEACR (Sparse Enrichment Analysis for 139 CUT&RUN) script to identify genomic regions enriched for each chromatin mark. 140 141 About 20000 peaks were obtained for each group (Fig 1C) and 10000~20000 peaks for each sample (Fig EV1C). The genome-wide peak distribution varied among different 142 modifications but showed no significant difference in the four groups (Fig 1C). For 143 H3K4me3, H3K27me3 and H3K27ac, most peaks were located in promoters and gene 144 bodies. H3K9me3 peaks mainly located in intergenic regions and gene bodies (Fig 1C). 145 The expected distribution of the four marks illustrated the reliance of our CUT&Tag 146 147 experimental procedure.

As OA exhibited lower H3K27me3 in genes than Normal (Fig 1B), we wondered 148 whether this change reflects an overall decrease or was restricted to a group of genes. To 149 elucidate genes with differential H3K27me3 and other histone marks, we calculated 150 peak strength that locate in each gene (TSS  $\pm/-2kb$ ). Indeed, about 7000 genes were 151 identified to have differential H3K27me3 strength in OA versus Normal, with more than 152 5000 genes lost H3K27me3 in OA (Fig 1D). Surprisingly, in Damaged versus Intact, 153 over 1000 genes lost H3K27me3 and very few genes gain H3K27me3 (Fig 1D), in 154 accordance with the overall decrease in tag density (Fig 1B). The dominance of 155 H3K27me3 down-regulated genes in both compares indicated the importance of this 156 H3K27me3 loss. Furthermore, the majority of genes that were found to lose H3K27me3 157 in Damaged versus Intact were also found in OA versus Normal (Fig 1E). These genes 158 gradually lost H3K27me3 from Normal to OA-Intact to OA-Damaged (Fig 1F). For 159 H3K4me3, more than 7000 genes showed a decrease in OA versus Normal, and over 160 1000 genes showed a decrease in Damaged versus Intact (Fig 1D and Fig EV2A). 161 However, the decrease of H3K4me3 was weaker than H3K27me3 (Fig 1F and Fig 162 EV2B). For H3K27ac and H3K9me3, relatively few differential genes were found in OA 163 versus Normal (Fig 1D). 164

As the histone modification peaks, especially H3K9me3, also distributed in intergenic 165 regions (Fig 1C), peaks outside genes with differential strength were calculated between 166 OA and Normal, Damaged and Intact (Fig 1G). However, few differential H3K9me3 167 peaks were found in both compares. Surprisingly, most differential H3K4me3 peaks 168 outside genes were up-regulated, in both OA versus Normal and Damaged versus Intact 169 (Fig 1, G and H). Moreover, the up-regulated H3K4me3 peaks were enriched around 170 centromere (Fig EV2C), while H3K27me3 didn't show similar pattern (Fig EV2D), 171 which needs further exploration. 172

Genome-wide correlation among all samples suggested that H3K27me3 was more
effective than the other three marks to distinguish between OA and Normal (Fig EV3).

### 175 Correlation between H3K27me3 loss and gene up-regulation in OA

To correlate histone modification to gene expression, transcriptomes of the
corresponding samples were analyzed (Fig 2A). In OA versus Normal, 583 genes were
down-regulated, and 297 genes were up-regulated. In Damaged versus Intact, 1327

- 179genes were down-regulated, and 657 genes were up-regulated. First, we plotted the RNA180expression levels against the modification levels in genes for normal samples (Fig 2B).181This analysis indicated that gene expression positively correlated with H3K4me3 and182H3K27ac in chondrocytes. The repressive mark H3K27me3 were associated with genes183expressed at low levels and negatively correlated with the expression levels. The184expected correlations further proved the reliability of our methods.
- 185 To elucidate the correlation between modification and gene expression changes, the RNA expression fold changes were plotted against the histone modification fold changes 186 in OA versus Normal and Damaged versus Intact (Fig 2C). The H3K27me3 187 modification changes inversely correlated with gene expression changes, and H3K27ac 188 positively correlated with gene expression. H3K4me3 changes positively correlated with 189 expression changes in Damaged versus Intact, but not in OA versus Normal. Overall, 190 191 OA samples exhibited strongest correlation between decreased H3K27me3 and upregulated gene expression (Fig 2C), consistent with the significant H3K27me3 loss in 192 OA (Fig 1, D and F). 193
- Additionally, we investigated the changes of histone modifications in up or down-194 regulated gene groups (Fig 2D). Surprisingly, H3K27me3 decreased markedly in up-195 regulated genes in both OA versus Normal and Damaged versus Intact, and H3K4me3 196 and H3K27ac level showed no significant change. This phenomenon indicated that the 197 gene up-regulation in OA mainly depends on the removal of repressive mark H3K27me3 198 rather than the addition of activating marks. For the down-regulated genes, H3K27ac 199 exhibited moderate decrease in both OA versus Normal and Damaged versus Intact (Fig 200 2D). Repressive mark H3K27me3 showed a slight decrease in OA versus Normal, which 201 may result from the global H3K27me3 loss in OA (Fig 1, B and D). H3K4me3 showed a 202 203 slight decrease in both down-regulated and up-regulated genes in OA versus Normal. This reflected an overall slight decrease of H3K4me3 (Fig 1D and Fig EV2B), which did 204 not affect gene expression. Specifically, 443 genes were identified to lose H3K27me3 205 and gain expression in OA versus Normal, with 328 genes in Damaged versus Intact, 206 and 128 genes in both compared groups (Fig 2E). The overlapped genes were highly 207 enriched in GO terms like inflammatory signaling and extracellular matrix organization 208 (Fig 2F), which are among the most typical changes in OA pathology, suggesting 209 biological significance of H3K27me3 loss-mediated gene derepression in OA. 210

### 211 H3K27me3 loss mediated up-regulation mainly occur on bivalent genes

As previously discovered, thousands of genes lost H3K27me3 in OA (Fig 1D) but only 212 hundreds of them were up-regulated (Fig 2E). We wondered whether other histone 213 marks contribute to this difference. Accordingly, we defined 12 chromatin states 214 carrying distinct combinations of the four histone marks using ChromHMM (Ernst & 215 Kellis, 2017) (Fig 3A). The enrichment of these chromatin states was examined at global 216 217 level and in specific genomic features in three normal samples (Fig EV4A). Genomewide correlation of chromatin states among all samples suggested better discrimination 218 219 between Normal and OA samples than each single histone mark (Fig EV4B and S3). 220 Then we defined the promoter state of each gene by the chromatin states of 2kb region around TSS (Fig 3B). The most prevalent promoter state was empty (state 12, 3) which 221 include about 20000 genes in Normal. Other promoter states were activating (states 9, 222 223 10, 11), repressive (states 5, 6, 7) and bivalent (state 8). H3K27me3 exist in states 5, 6, 7 and 8. Surprisingly, genes with bivalent promoters (state 8) account for more than 2000 224

in Normal and decreased by half in OA (Fig 3B). As bivalent domains are well known in
embryonic stem cells but not in terminal-differentiated cells, we wondered whether the
observed bivalency came from mixed populations of cells that carry either repressive or
activating marks at a given locus. However, the very low expression level of these genes
in normal chondrocytes (Fig 3I) didn't support the exist of activating cell population.
Although terminally differentiated, normal articular chondrocytes still harbored plenty of
bivalent genes.

To find out if the loss of H2K27me3 has preference for bivalent promoters, we looked 232 into the promoter states of about 5000 genes that lost H3K27me3 in OA versus Normal 233 234 (Fig 1D). However, both bivalent (state 8) and repressive (state 6) genes exhibited significant enrichment in Normal (Fig 3C), with about a half of all genes in each state 235 lost H3K27me3. Accordingly, genes in state 8 and 6 decreased significantly from 236 237 Normal to OA (Fig 3C). Genes in state 9 and 7 increased in OA, which may result from the loss of H3K27me3 in state 8 and 6. Next we plotted the Log<sub>2</sub> fold change of 238 H3K27me3 in OA versus Normal for genes in states 5 to 8 (Fig 3D). Interestingly, genes 239 in state 8 showed significantly more H3K27me3 down-regulation than other three 240 groups. What's more, the overall gene expression level of state 8 exhibited a significant 241 up-regulation from Normal to OA, whereas genes in state 5-7 did not express in both 242 Normal and OA (Fig 3E). These results suggested that H3K27me3 loss occurred mainly 243 on genes of state 8 and 6. While only state 8, namely bivalent genes, resulted in the up-244 regulation of gene expression, which may due to the pre-exist of activating mark 245 H3K4me3. 246

Next, we want to know the contribution of bivalent genes de-repression on the overall gene up-regulation. Among the 297 genes that up-regulated in OA versus Normal, genes with primed promoter (state 9) account for the largest proportion (Fig 3F). However, genes with active promoter (state 10) showed no increase in OA, we assumed that these genes used other transcriptional or post-transcriptional mechanism to increase expression level. Importantly, the most significant state change from Normal to OA is the loss of bivalent genes and increase of primed genes (Fig 3F).

254 State transition analysis verified the transition from bivalent genes in Normal to primed 255 genes in OA (Fig 3G, state 8 to 9). Other obvious transitions include state 6 to 7, 7 to 12 256 and 5 to 2, which all attributed to the loss of H3K27me3. However, some bivalent genes 257 also lost H3K4me3 to become repression (state 6).

# Bivalent genes derepression in OA resembles growth plate chondrocytes hypertrophy

We further analyzed states transitions of the 2346 bivalent genes in each sample (Fig 260 3H). A lot of bivalent genes lost H3K27me3 or H3K4me3 in OA. Especially, some OA 261 262 samples exhibited an overall H3K27me3 loss (O28, O27-Dam). Paired samples also showed more H3K27me3 loss in Dam versus Int. Bivalent genes lost H3K27me3 in OA 263 are enriched in GO terms that include cell migration, extracellular matrix organization, 264 What signaling pathway and ion transport (Fig 3I). Bivalent domains are deemed to poise 265 developmental genes for future activation, whereas articular chondrocytes are meant to 266 persist to form permanent cartilage. Originating from the same cartilage mass, growth 267 plate chondrocytes undergo proliferation, hypertrophy and apoptosis, which promotes 268 degradation and calcification of cartilage matrix to drive bone growth. OA pathogenesis 269

- commonly includes a switch from the articular to the growth plate chondrocyte
  phenotype, and re-initiation of proliferation and hypertrophy (Pitsillides & Beier, 2011).
- We wondered whether the bivalent genes need to be activated during the proliferation 272 and hypertrophy of growth plate chondrocytes but remain as a developmental legacy 273 274 feature in articular chondrocytes. Re-analysis of the epigenetic data from a mouse study (Wuelling et al, 2021) revealed 162 bivalent genes in proliferating chondrocytes that lost 275 276 H3K27me3 in hypertrophic chondrocytes (Fig EV4, C to E) (Table S3). GO analysis revealed enrichment in several terms like multicellular organism development and ion 277 transport (Fig 3I). Overlapping GO terms between OA and growth plate chondrocytes 278 279 hypertrophy suggested the similarity between the two process.
- Next, we defined the bivalent genes that lose H3K27me3 or H3K4me3 in OA versus 280 281 Normal and Damaged versus Intact. Apparently, the vast majority of the altered bivalent genes lose H3K27me3 and only a very small number lose H3K4me3 (Fig 3J). 282 Furthermore, the bivalent genes lost H3K27me3 tend to obtain higher expression level in 283 both OA versus Normal and Damaged versus Intact (Fig 3, J and K). Typical bivalent 284 genes that lose H3K27me3 and gain expression in OA were shown (Fig 3L). These data 285 suggest that H3K27me3 loss in bivalent promoters up-regulate gene expression in OA 286 articular chondrocytes, which is consistent to the hypertrophy and ossification of growth 287 plate chondrocytes. 288

#### 289 Inflammation induced H3K27 demethylase expression in OA chondrocytes

Next, we wondered what caused the loss of H3K27me3 on bivalent promoters in OA. 290 H3K27me3 are added by the PRC2 complex that consist EZH1/2, EED and SUZ12, and 291 292 removed by KDM6A and KDM6B (Xiang et al, 2007; Hong et al, 2007; Agger et al, 2007; De Santa et al. 2007). However, the RNA expression of these methyltransferases 293 and demethylases in our RNA-seq dataset showed no significant difference in OA versus 294 295 Normal and Damaged versus Intact (Fig EV5). Inflammation plays an important role in the development of OA. Proinflammatory cytokines like IL-1 $\beta$  downregulate the 296 synthesis of major extracellular matrix (ECM) components and induce the production of 297 proteolytic enzymes of chondrocytes. Thus, IL-1 $\beta$  is widely used to create a cellular 298 model of OA. Interestingly, IL-1ß treatment increased the expression of H3K27me3 299 demethylases in human chondrocytes from OA patients (Fig 4A), with a higher 300 induction ratio of KDM6B than KDM6A. It has been reported that KDM6B (JMJD3) 301 contributes to the control of gene expression in LPS-activated macrophages (De Santa et 302 al, 2007, 2009) and is involved in inflammatory diseases. More importantly, KDM6B 303 has been reported to promote chondrocyte proliferation and hypertrophy in endochondral 304 bone formation (Zhang et al, 2015, 3). These results suggested KDM6B as a candidate 305 for H3K27me3 loss in OA. However, KDM6B showed no statistic difference in human 306 normal and OA cartilage by immunofluorescence (IF) staining (Fig 4, B and C), in 307 308 which KDM6B positive cells were around 50% in both groups. However, acute inflammation is contraindicated for knee replacement. So, the OA cartilage samples we 309 collected here were inflammation quiescent and may not exhibit KDM6B up-regulation. 310 311 A time course that simulating the transient inflammation in OA patients detected the fall back of KDM6B after IL-1 $\beta$  removal (Fig 4D). We then established a rat surgical 312 instability OA model to examine KDM6B in cartilage and synovial inflammation by 313 314 *H&E* staining. OA synovium exhibited typical hyperplasia and plenty of inflammatory cells in both 4w and 8w (Fig 4E). Interestingly, KDM6B positive cells raised from 315

sporadic in shame to about 50% in OA (Fig 4F). These data suggest that inflammation
induces the expression of KDM6B, which may be responsible for the H3K27me3 loss in
OA chondrocytes.

## 319KDM6 inhibitor rescued inflammation-induced H3K27me3 loss and abnormal gene320expression

- 321 We tested whether the inflammation induction of KDM6B causes H3K27me3 loss in human OA chondrocytes by CUT&Tag. It was found that IL-1ß treatment resulted in a 322 significant H3K27me3 decrease across gene bodies on the whole genome (Fig 5A). 323 Interestingly, 48hr after the withdraw of IL-1β, with the expression level of KDM6B fell 324 back (Fig 4D), the H3K27me3 level didn't recover. This may explain the contradiction 325 of H3K27me3 loss and normal KDM6B level in OA patients (Fig 4, B and C). Acute 326 327 inflammation in OA patients induce the transient expression of KDM6B, which may result in H3K27me3 loss that could persist even after the acute inflammation. 328
- To verify the importance of KDM6B in this process, we used a selective KDM6 329 inhibitor, GSK-J4 (Kruidenier et al, 2012). Surprisingly, combined utilization of GSK-J4 330 and IL-1ß completely inhibited this H3K27me3 loss (Fig 5B). 3661 genes were 331 identified to lose H3K27me3 upon IL-1 $\beta$  and simultaneously rescued by GSK-J4, which 332 333 contain 569 genes of the previously found 728 genes that lose H3K27me3 in OA versus Normal and Damaged versus Intact (Fig 5C). Furthermore, the overlapped 569 genes 334 showed higher H3K27me3 in control and GSK-J4 rescued samples than the rest 3092 335 genes (Fig 5D), suggesting the consistence between in vivo and in vitro conditions. 336 Typical genes that lost H3K27me3 upon IL-1ß and restored H3K27me3 by GSK-J4 337 were shown (Fig 5E). Accordingly, their gene expression level increased upon IL-1 $\beta$  and 338 339 were repressed by GSK-J4 (Fig 5F). Therefore, a key role of KDM6B was proposed in inflammation induced H3K27me3 loss and abnormal gene expression in OA 340 chondrocytes (Fig 6). 341
- Altogether, our data revealed the loss of H3K27me3 and de-repression of bivalent genes
   that caused chondrocyte hypertrophy in OA. Inflammation induced the expression of the
   H3K27me3 demethylase KDM6B, thus provides epigenetic mechanism for IL-1β
   induced cartilage destruction.
- 346

## 347 **Discussion**

Our study, for the first time, provides a genome-wide histone modification map for OA 348 chondrocytes. The most significant change in OA is the loss of repressive mark 349 H3K27me3 on promotors, which in turn lead to up-regulation of OA related genes. 350 Surprisingly, in normal chondrocytes plenty of genes are bivalent, allowing easily 351 activation upon H3K27me3 loss in OA, which resemble hypertrophy related genes in 352 growth plate chondrocytes. This finding provides novel epigenetic evidence for the 353 developmental explanation for OA. Further investigation revealed that H3K27me3 354 demethylase KDM6B is highly expressed in a rat OA model and also induced by IL-1β 355 in human OA chondrocytes. IL-1ß treatment leads to significant H3K27me3 loss and up-356 regulation of OA related genes. While a KDM6B inhibitor, GSK-J4, fully restores 357 H3K27me3 and partially down-regulates gene expression, which serves as an attractive 358 therapeutic strategy for OA. 359

- Several studies have addressed the importance of H3K27me3 methyltransferases and 360 demethylases in cartilage development and OA. Loss of PRC2 components Ezh2 or Eed 361 in murine chondrocytes accelerate hypertrophic differentiation and stimulates an 362 osteogenic transcriptional program (Camilleri et al, 2018, 2; Mirzamohammadi et al, 363 2016), highlighting the importance of H3K27me3 in suppressing Wnt and TGF-B 364 signaling. Another study found that EZH2 was highly expressed in a subpopulation of 365 OA patients and ameliorates OA by inhibiting hypertrophy (Du et al, 2020, 2), 366 367 consistent with our findings. Before the finding in endochondral bone formation (Zhang et al, 2015, 3), KDM6B is known to be an inducible enzyme that plays key roles in 368 development (Agger et al, 2007; Estarás et al, 2012) and inflammatory response (De 369 Santa et al. 2007, 2009). The effect of KDM6B in OA is controversy. One study 370 reported that knockdown of Kdm6b in mouse chondrocytes leads to accelerated OA 371 progression, with the number of Kdm6b-positive chondrocytes lower in both mice and 372 373 human OA cartilage samples (Dai et al, 2017). While other studies reported an increased expression of KDM6B in OA chondrocytes, and GSK-J4 prevented the expression of 374 pro-inflammatory cytokines and catabolic enzymes (Yapp et al, 2016, 3; Jun et al, 375 2020). Furthermore, the latter study demonstrated a cartilage protection effect of GSK-376 377 J4 in a surgically induced mouse OA model (Jun et al, 2020).
- Our research on human OA cartilage samples showed a significant loss of H3K27me3 378 genome-wide and especially on hypertrophic genes, supporting an OA promoting effect 379 for KDM6B. We also found KDM6B up-regulation in a rat OA model and IL-1β treated 380 381 human OA chondrocytes, but not in human OA specimen. In addition to the inflammation quiescent explanation we discussed above, another possibility is the 382 dysregulation of cofactors that bring KDM6B to specific genome locus. As GSK-J4 is an 383 inhibitor of both KDM6B and KDM6A, mapping global targets of this two demethylases 384 and putative cofactors in OA cartilage can provide us better insights into the putative 385 candidature of GSK-J4 and related molecules for OA therapeutics. In addition, we found 386 an increase of H3K4me3 in intergenic regions indicating the loss of preciseness in 387 epigenetic regulation that requires further investigation. 388
- In this study, we found that inflammation induced KDM6B lead to a significant decrease of H3K27me3 which lead to the activation of bivalent genes in OA. Our results suggest an inherited epigenetic signature that makes articular chondrocytes prone to hypertrophy and ossification and contribute to a promising epigenetic therapy for OA.
- 393 394

## 395 Materials and Methods

## **Human articular cartilage samples**

- Experiments involving human subjects were performed according to the Ethics 397 Committee on Biomedical Research, West China Hospital of Sichuan University. 398 Informed consent was obtained from patients. OA cartilage tissues were obtained from 399 patients undergoing total knee arthroplasty due to end-stage OA at West China Hospital. 400 Normal cartilage tissues were obtained from individuals undergoing amputation (without 401 OA). The whole layer of cartilage from medial and lateral femoral condyle were cut into 402 small pieces and digested by 4mg/ml PRONASE Protease (Millipore, 53702) for 1hr 403 followed by 1mg/ml collagenase (Nordmark, S1746502) in DMEM/F12 with 10% FBS 404 overnight. The dissociated chondrocytes were then used for CUT&Tag and RNA-seq 405 library construction. 406
- 407 **CUT&Tag library construction and sequencing**

CUT&Tag libraries were constructed as previously described (Kaya-Okur et al, 2020). 408 409 In brief, chondrocytes were lysed to acquire nuclei and bind to Concanavalin-coated magnetic beads (Polysciences, 86057). Beads were incubated successively with the 410 primary antibody (Anti-H3K4me3, Abcam, ab8580; Anti-H3K27me3, Active motif, 411 412 39055; Anti-H3K27ac, Abcam, ab177178; Anti-H3K9me3, Abcam, ab176916), the secondary antibody (Goat Anti-Rabbit IgG(H+L), Abclonal, AS070) and pG-Tn5 413 (Vazyme, S602) loaded with mosaic-end adapters. Tn5 was activated by addition of 414  $Mg^{2+}$ . DNA was released in a small volume of SDS. Samples were enriched by PCR 415 amplification (NEBNext, 2X PCR premix, M0541) followed by magnetic bead cleanup 416 (Vazyme, N411) and sent for paired-end 150-bp sequencing performed on an Illumina 417 HiSeq 2500 platform. 418

## 419 Rat OA model

Experiments involving animal subjects were performed in accordance with Institutional 420 Animal Care and Use Committee (IACUC) of the Sichuan University-approved 421 422 protocols. Six-week-old male SD rats were purchased from Chengdu Enswille Biotechnology Co., LTD. Two weeks after adaptation, the OA model was established by 423 anterior cruciate ligament transection (ACLT) plus destabilization of the medial 424 meniscus (DMM) under isoflurane anesthesia. Briefly, the skin was cut approximately 425 2cm along the medial side of the knee joint, and the tissue was subsequently separated 426 until the patellar ligament was exposed. The joint capsule was opened medial to the 427 428 patellar ligament. After cutting the anterior cruciate ligament, the anterior horn of the medial meniscus was carefully removed along the medial edge of the tibial plateau 429 (sham operation group only opened the joint capsule without other surgery), and finally 430 431 the joint capsule, muscle and skin were sutured. At four or eighth week after surgery, rats were sacrificed under isoflurane anaesthetization. 432

## 433 Cell culture and treatment

434 The dissociated chondrocytes were cultured in DMEM/F12 with 2% FBS. For time 435 course that simulating the acute inflammation, 5ng/ml IL-1 $\beta$  was added for 2days and 436 then removed for another 2 days. For the rescue experiment, 5ng/ml IL-1 $\beta$  alone or in 437 combination with 5uM GSK-J4 (abmole, M5149) were added for 48hrs.

## 438 CUT&Tag data processing

Read quality of the raw sequences was verified with fastqc (0.11.9). All sequence reads 439 were then aligned to the hg38 build of the human reference genome by bowtie2 (2.3.5.1)440 using --end-to-end --very-sensitive --no-mixed --no-discordant --phred33 -I 10 -X 700 441 parameters. Duplication rate of each sample was checked with Picard tools (2.3.1). 442 Mapped reads were normalized to 1 million to generate histone modification enrichment 443 around genes with deeptools (3.5.1) (Ramírez et al, 2016). For H3K4me3, H3K27me3, 444 445 H3K27ac and H3K9me3, to assess data reproducibility between different samples, correlation analysis of normalized mapped reads counts in each 500-bp bins across the 446 whole genome was calculated. 447

All CUT&Tag peaks were called by SEACR (1.3) (Meers *et al*, 2019) with parameters
0.01 non stringent. Subsequently, these identified peaks were classified into five
categories with the following order: promoter, gene body, enhancer, region 10kb nearby
TSS and intergenic region. To calculate the differential peaks of particular histone
modification, we combined all the mapped reads of each sample to identify "common"
peaks of this histone modification. The tags abundance of each peak in Normal, OA,
OA-Int and OA-Dam sample was quantified independently and limma was used for

differential expression analysis. The peaks exhibiting tags abundance foldchange >2 or 455 <0.5 and P-value <0.05 over OA to Normal or OA-Dam to OA-Int were defined as up-456 regulated or down-regulated peaks. To calculate the differential genes of particular 457 histone modification, we calculated the tags abundance on all gene promoters, which 458 were defined as +- 2kb region around the TSS of each gene, in each sample. The genes 459 exhibiting tags abundance foldchange >2 or <0.5 and P-value <0.05 over OA to Normal 460 or OA-Dam to OA-Int were defined as up-regulated or down-regulated genes. The 461 mapped CUT&Tag reads and identified peaks were visualized on the Integrative 462 Genomics Viewer (IGV). 463

### 464 **RNA-seq data processing**

Hisat2 (2.1.0) software was used to align the clean sequencing reads to the human 465 reference genome (hg38) with parameters (--no-unal --rna-strandness FR --fr). 466 Expression levels for all genes were quantified to fragments per kilobase million 467 (FPKM) using Stringite (2.2.0) with default parameters. Subsequently, edge R was used 468 469 for differential expression analysis. The genes with expression level fold change >2 or <0.5 and P-vaule <0.05 was defined as up-regulated genes or down-regulated genes 470 respectively. Gene Ontology analysis were performed using DAVID (Sherman et al, 471 2022). 472

#### 473 Histone modifications and its correlation with gene expression

To quantify correlation of histone modification levels with gene expression value, tags in identified peaks which overlapped with gene promoters were summed and normalized for each gene to represent the modification levels. The genes were then ranked and binned by its modification levels. Each bin of genes (100) is represented by a dot on the plot, with the arithmetic mean of histone modification and gene expression levels to stand for the histone modification and gene expression level of the bin.

480 To quantify correlation of histone modification changes with gene expression changes, 481 the modification levels of each gene was also calculated as the same manner. The 482 change of modification level and gene expression level was calculated as the logarithm 483 of the ratio of the normalized modification levels and gene expression levels in OA 484 versus Normal or OA-Dam versus OA-Int. The genes were then ranked and binned by 485 its modification changes, with the average of their expression changes and modification 486 changes to represent one dot in the plot.

### 487 **Defining epigenetic states with ChromHMM**

488 The mapped CUT&Tag reads were used as input for ChromHMM (1.24) (Ernst & Kellis, 2012). The whole genome was segmented into non-overlapping bins of 200 bp. A 489 multivariate Hidden Markov Model was used to model the combinatorial and spatial 490 patterns from H3K4me3, H3K27me3, H3K27ac and H3K9me3 markers in each bin. 491 Based on their estimated log-likelihoods, the 12-state ChromHMM model was selected. 492 According to the combinatorial patterns of 4 histone markers of each state, we defined 493 494 these states as H3K9me3-H3K4me3, HeteroChromatin, Empty, Weak HeteroChromatin, Silenced gene, Repression, Weak Repression, Bivalent promoter, Primed promoter, 495 Active promoter, Enhancer and empty. To assess the robustness of trained model 496 between different samples, we used kappa analysis to evaluate the state agreement 497 between Normal, OA, OA-Int and OA-Dam subsets. The fold enrichment of each 498 ChromHMM state was also quantified at Refseq gene, Refseq exon, RefSeq TSS, 499 500 RefSeq TSS, +-2kb region around RefSeq TSS and CpG islands.

### 501 Analysis of ChromHMM bivalent promoter state transition

For ChromHMM bivalent promoter state transition analysis of Normal to OA and OA-502 Int to OA-Dam, we calculated the bivalent promoter state occurrence in +- 1kb region 503 around TSS (10 ChromHMM bins) of each gene. The genes with at least 7 bivalent 504 promoter state in at least 2 of 3 Normal samples was defined as bivalent genes. We then 505 count and plot heatmap to show the occurrence of ChromHMM state transition in +- 1kb 506 region around TSS of each bivalent gene in OA, OA-Int and OA-Dam subsets. For each 507 bivalent gene, "H3K27me3 loss" was happened in the subset if there was at least 4 508 509 ChromHMM primed promoter or active promoter state occurred, "H3K4me3 loss" was happened in the subset if there was at least 4 ChromHMM repression state occurred, 510 "bivalent" was happened in the subset if there was still at least 6 ChromHMM bivalent 511 promoter state occurred. 512

To figure out the genes with H3K27me3 loss and H3K4me3 loss in the process of 513 Normal to OA or OA-Int to OA-Dam, we first defined the states transition of each bin 514 according to the occurrence in all samples. The bins with at least 2 ChromHMM primed 515 promoter or active promoter state in 4 OA subsets were defined as H3K27me3 loss bins 516 in OA, the bins with at least 1 ChromHMM primed promoter or active promoter state in 517 2 OA-Int or OA-Dam subsets were defined as H3K27me3 loss bins in OA-Int or OA-518 519 Dam, the bins with at least 2 ChromHMM repression state in 4 OA subsets as H3K4me3 loss bins in OA, the bins with at least 1 ChromHMM repression state in 2 OA-Int or OA-520 Dam subsets as H3K4me3 loss bins in OA-Int or OA-Dam. The genes with at least 40% 521 bivalent bins occurred H3K27me3 loss or H3K4me3 loss was defined as H3K27me3 522 523 loss genes or H3K4me3 loss genes. The expression levels in Normal, OA, OA-Int and OA-Dam and expression changes between them were then counted and plotted. 524

### 525 Statistical analysis

526Analyses were performed using GraphPad Prism 9.0 (GraphPad Software, USA). All527data were presented as means  $\pm$  SDs. Statistical comparisons of two groups were528performed by two-tailed ratio paired or unpaired t test. Multiple comparisons were made529using ordinary one-way ANOVA followed by Tukey's multiple comparisons test.530Statistical significance (\*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001; \*\*\*\*P < 0.0001) was</td>531indicated in figures.

### 533 Data availability

534The CUT&Tag and RNA-seq data generated in this study have been deposited in the535NCBI's Sequence Read Archive (SRA) database under accession code PRJNA930583.536The mouse PC and HC ChIP-seq data was downloaded through the GEO accession537numbers. All code required for data analyses and figure preparation are available at538https://github.com/luciferase1234/Inflammation-induced-epigenetic-activation-of-539bivalent-genes-in-osteoarthritic-cartilage. All data are available in the main text or the540supplementary materials.

541

532

### 542 Acknowledgments

543 We are grateful to the IT Center of west china hospital for supplying the computing 544 resources. We thank Professor Hongjie Shen for his advice and criticism. This work was

- 545 supported by National Natural Science Foundation of China (81874027, U22A20280);
- 546 Science & Technology Department of Sichuan Province (2023NSFSC1607,
- 547 2021YFSY0003, 2022YFS0051, 2022NSFSC1312); Shenzhen-HongKong Institute of
- 548 Brain Science-Shenzhen Fundamental Research Institutions (312200102); Clinical

Research Incubation project of West China Hospital of Sichuan University 549 550 (2021HXFH036). 551 **Author contributions** 552 HD conceived the project, designed and performed the experiments, analyzed the data, 553 and wrote the manuscript. YZhang co-conceived the project, did all the bioinformatics 554 analysis and prepared figures. XYu and DW performed cell isolations. XYou performed 555 immunofluorescence microscopy and helped with Cut&Tag. ZLuo and YC performed 556 animal experiments. HL and ZLiao participated in clinical sample acquisition. B-SD, 557 YZhao and YW provided suggestions and revised the manuscript. KX drawed part of the 558 working model. FY, FG, NN and JZ revised the manuscript. ZZ and SH supervised the 559 work and revised the manuscript. 560 **Disclosure and competing interests statement** 561 The authors declare that they have no conflict of interest. 562 563 564 References 565 Agger K, Cloos PAC, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E, 566 Salcini AE & Helin K (2007) UTX and JMJD3 are histone H3K27 demethylases 567 involved in HOX gene regulation and development. Nature 449: 731-734 568 569 Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, et al (2019) OARSI guidelines for the non-570 surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and 571 Cartilage 27: 1578–1589 572 Camilleri ET, Dudakovic A, Riester SM, Galeano-Garces C, Paradise CR, Bradley EW, 573 McGee-Lawrence ME, Im H-J, Karperien M, Krych AJ, et al (2018) Loss of histone 574 575 methyltransferase Ezh2 stimulates an osteogenic transcriptional program in chondrocytes but does not affect cartilage development. Journal of Biological Chemistry 576 293: 19001-19011 577 578 Dai J, Yu D, Wang Y, Chen Y, Sun H, Zhang X, Zhu S, Pan Z, Heng BC, Zhang S, et al (2017) Kdm6b regulates cartilage development and homeostasis through anabolic metabolism. 579 580 Ann Rheum Dis 76: 1295–1303 De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M, 581 582 Notarbartolo S, Casola S, et al (2009) Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 28: 3341-3352 583 584 De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G & Natoli G (2007) The Histone H3 Lysine-27 Demethylase Jmjd3 Links Inflammation to Inhibition of Polycomb-585 Mediated Gene Silencing. Cell 130: 1083-1094 586 Du X, Chen Y, Zhang Q, Lin J, Yu Y, Pan Z, Sun H, Yuan C, Yu D, Wu H, et al (2020) Ezh2 587 Ameliorates Osteoarthritis by Activating TNFSF13B. J Bone Miner Res 35: 956-965 588 Dudakovic A, Camilleri ET, Xu F, Riester SM, McGee-Lawrence ME, Bradley EW, Paradise 589 CR, Lewallen EA, Thaler R, Deyle DR, et al (2015) Epigenetic Control of Skeletal 590

591 592	Development by the Histone Methyltransferase Ezh2. <i>Journal of Biological Chemistry</i> 290: 27604–27617
593 594	Ernst J & Kellis M (2012) ChromHMM: automating chromatin-state discovery and characterization. <i>Nat Methods</i> 9: 215–216
595 596	Ernst J & Kellis M (2017) Chromatin-state discovery and genome annotation with ChromHMM. <i>Nat Protoc</i> 12: 2478–2492
597 598 599	Estarás C, Akizu N, García A, Beltrán S, de la Cruz X & Martínez-Balbás MA (2012) Genome- wide analysis reveals that Smad3 and JMJD3 HDM co-activate the neural developmental program. <i>Development</i> 139: 2681–2691
600 601	Grandi FC & Bhutani N (2020) Epigenetic Therapies for Osteoarthritis. <i>Trends in Pharmacological Sciences</i> 41: 557–569
602 603 604	Hong S, Cho Y-W, Yu L-R, Yu H, Veenstra TD & Ge K (2007) Identification of JmjC domain- containing UTX and JMJD3 as histone H3 lysine 27 demethylases. <i>Proc Natl Acad Sci</i> <i>U S A</i> 104: 18439–18444
605 606	Hyun K, Jeon J, Park K & Kim J (2017) Writing, erasing and reading histone lysine methylations. <i>Exp Mol Med</i> 49: e324–e324
607 608 609	Jun Z, Xinmeng J, Yue L, Zhi W, Yan Z, Tieyi Y & Jiangan T (2020) Jumonji domain containing-3 (JMJD3) inhibition attenuates IL-1β-induced chondrocytes damage in vitro and protects osteoarthritis cartilage in vivo. <i>Inflamm Res</i> 69: 657–666
610 611 612 613	Karsdal MA, Michaelis M, Ladel C, Siebuhr AS, Bihlet AR, Andersen JR, Guehring H, Christiansen C, Bay-Jensen AC & Kraus VB (2016) Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. <i>Osteoarthritis Cartilage</i> 24: 2013–2021
614 615	Kaya-Okur HS, Janssens DH, Henikoff JG, Ahmad K & Henikoff S (2020) Efficient low-cost chromatin profiling with CUT&Tag. <i>Nat Protoc</i> 15: 3264–3283
616 617 618	<ul> <li>Kruidenier L, Chung C, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C,</li> <li>Bridges A, Diallo H, <i>et al</i> (2012) A selective jumonji H3K27 demethylase inhibitor</li> <li>modulates the proinflammatory macrophage response. <i>Nature</i> 488: 404–408</li> </ul>
619 620	Ling C & Rönn T (2019) Epigenetics in Human Obesity and Type 2 Diabetes. <i>Cell Metabolism</i> 29: 1028–1044
621 622	Meers MP, Tenenbaum D & Henikoff S (2019) Peak calling by Sparse Enrichment Analysis for CUT&RUN chromatin profiling. <i>Epigenetics &amp; Chromatin</i> 12: 42
623 624 625	Millán-Zambrano G, Burton A, Bannister AJ & Schneider R (2022) Histone post-translational modifications — cause and consequence of genome function. <i>Nat Rev Genet</i> 23: 563–580

626 627 628	Mirzamohammadi F, Papaioannou G, Inloes JB, Rankin EB, Xie H, Schipani E, Orkin SH & Kobayashi T (2016) Polycomb repressive complex 2 regulates skeletal growth by suppressing Wnt and TGF-β signalling. <i>Nat Commun</i> 7: 12047
629 630 631	Monteagudo S, Cornelis FMF, Aznar-Lopez C, Yibmantasiri P, Guns L-A, Carmeliet P, Cailotto F & Lories RJ (2017) DOT1L safeguards cartilage homeostasis and protects against osteoarthritis. <i>Nat Commun</i> 8: 15889
632 633	Pitsillides AA & Beier F (2011) Cartilage biology in osteoarthritis—lessons from developmental biology. <i>Nat Rev Rheumatol</i> 7: 654–663
634	Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dündar F &
635	Manke T (2016) deepTools2: a next generation web server for deep-sequencing data
636	analysis. <i>Nucleic Acids Research</i> 44: W160–W165
637 638	Reynard LN (2017) Analysis of genetics and DNA methylation in osteoarthritis: What have we learnt about the disease? <i>Seminars in Cell &amp; Developmental Biology</i> 62: 57–66
639	Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T & Chang W (2022)
640	DAVID: a web server for functional enrichment analysis and functional annotation of
641	gene lists (2021 update). <i>Nucleic Acids Res</i> 50: W216-221
642	Smeriglio P, Grandi FC, Davala S, Masarapu V, Indelli PF, Goodman SB & Bhutani N (2020)
643	Inhibition of TET1 prevents the development of osteoarthritis and reveals the 5hmC
644	landscape that orchestrates pathogenesis. <i>Sci Transl Med</i> 12: eaax2332
645	Taylor SEB, Li YH, Wong WH & Bhutani N (2015) Genome-Wide Mapping of DNA
646	Hydroxymethylation in Osteoarthritic Chondrocytes: DYNAMICS OF 5hmC IN OA.
647	Arthritis & Rheumatology 67: 2129–2140
648 649 650 651 652	Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, <i>et al</i> (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>The Lancet</i> 390: 1211–1259
653	Wuelling M, Neu C, Thiesen AM, Kitanovski S, Cao Y, Lange A, Westendorf AM, Hoffmann
654	D & Vortkamp A (2021) Epigenetic Mechanisms Mediating Cell State Transitions in
655	Chondrocytes. J Bone Miner Res 36: 968–985
656 657	Xiang Y, Zhu Z, Han G, Lin H, Xu L & Chen CD (2007) JMJD3 is a histone H3K27 demethylase. <i>Cell Res</i> 17: 850–857
658	Yang J-H, Hayano M, Griffin P, Amorim JA, Bonkowski MS, Apostolides JK, Blanchette M,
659	Munding EM, Bhakta M, Salfati EL, <i>et al</i> (2021) Loss of Epigenetic Information as a
660	Cause of Mammalian Aging. <i>SSRN Journal</i>
661	Yapp C, Carr AJ, Price A, Oppermann U & Snelling SJB (2016) H3K27me3 demethylases
662	regulate in vitro chondrogenesis and chondrocyte activity in osteoarthritis. Arthritis Res
663	Ther 18: 158

Zhang F, Xu L, Xu L, Xu Q, Li D, Yang Y, Karsenty G & Chen CD (2015) JMJD3 promotes 664 chondrocyte proliferation and hypertrophy during endochondral bone formation in mice. 665 Journal of Molecular Cell Biology 7: 23–34 666 Zhang W, Qu J, Liu G-H & Belmonte JCI (2020) The ageing epigenome and its rejuvenation. 667 Nat Rev Mol Cell Biol 21: 137–150 668 669 670 671 672 **Figure legends** 673 674 Figure 1. Histone modification profiling of normal and OA chondrocytes. 675 676 (A) Schematic diagram of the experimental design. Chondrocytes from Normal (n=3), OA (n=5), OA-Intact and OA-Damaged (Paired, n=2) samples were used for CUT&Tag and 677 RNA-seq. 678 (B) Tag density of each histone mark across the gene bodies (+/-5kb) in Normal and OA (left), 679 paired OA-intact and OA-damaged (right). 680 (C) Genome-wide peak distribution of each modification in Normal, OA, OA-intact and OA-681 damaged samples. The numbers of peaks in promoter, gene body, enhancer, 10kb nearby 682 gene body, and intergenic regions are shown. 683 (D) The numbers of differential modified genes (log2FC>0.58, p-value<0.05) between Normal 684 and OA, OA-intact and OA-damaged for each histone mark. 685 (E) Venn diagram of genes which lose H3K27me3 in OA vs. Normal and OA-Damaged vs. 686 OA-Intact. 687 (F) Tag density and heatmap of H3K27me3 across the gene bodies (+/-5kb) of genes which loss 688 H3K27me3 in OA vs. Normal, OA-Damaged vs. OA-Intact and both. 689 690 (G) The numbers of differential peaks outside genes (log2FC>0.58, p-value<0.05) between 691 Normal and OA, OA-intact and OA-damaged for each histone mark. (H) Distribution of up-regulated peaks outside genes for H3K4me3 and H3K27me3 in OA vs. 692 Normal. 693 694 Figure 2. Correlation between histone modification and differential gene expression. 695 (A) Heatmap of differential gene expression (log2FC>0.58) between Normal and OA, OA-696 intact and OA-damaged. 697 698 (B) Correlation between each histone modification and gene expression in normal chondrocytes. Genes were grouped to 100 gene (one dot in the online supplemental figure) sets according 699 to each histone modification level. 700 (C) Pearson correlation between changes in histone modification and gene expression for OA 701 vs. Normal and OA-Damaged vs. OA-Intact. The fold changes in both expression level and 702 histone modification level were calculated for each gene. The genes were grouped into 100 703 gene sets according to their histone modification changes. 704

705 706 707	(D) Tag density of H3K27me3, H3K4me3 and H3K27ac across the gene bodies (+/-5kb) of genes up-regulated or down-regulated expression in OA vs. Normal and OA-Damaged vs. OA-Intact.
708 709	(E) Venn diagram of genes which lose H3K27me3 and gain expression in OA vs. Normal and OA-Damaged vs. OA-Intact.
710 711	(F) GO terms with the highest enrichment of 128 genes which lose H3K27me3 and gain expression in both OA vs. Normal and OA-Damaged vs. OA-Intact.
712	
713	Figure 3. H3K27me3 loss in bivalent promoters up-regulate gene expression in OA.
714 715	(A) Chromatin state definitions (emission probabilities) of a 12-state ChromHMM model based on the Normal, OA, OA-intact and OA-damaged data sets.
716 717	(B) Promoter state define of all genes in each Normal and OA sample by the chromatin states of 2kb region around TSS.
718	(C) Promoter state distribution of genes that lose H3K27me3 in OA vs. Normal.
719 720 721 722	(D) Box plot showing the H3K27me3 changes of genes that lose H3K27me3 in OA vs. Normal with promoter state 5-8 in Normal. The significance of difference among all states was calculated by ANOVA test, and the significance of difference between state 8 and other states was determined by two side t test.
723 724	(E) Box plot showing the RNA expression changes of genes that lose H3K27me3 in OA vs. Normal with promoter state 5-8 in Normal.
725	(F) Promoter state distribution of up-regulated genes in OA vs. Normal.
726 727	(G) Promoter state transitions of all genes from normal to OA. The transition ratio was normalized by the count of genes of each state in Normal.
728 729	(H) Heatmap showing the K4/K27 bivalent promoters in normal samples and their state changes in OA, OA-Intact and OA-Damaged samples.
730 731 732	(I) GO terms with the highest enrichment of bivalent genes which lose H3K27me3 in OA and their enrichment score of bivalent genes that lose H3K27me3 during endochondral ossification.
733 734	(J) Dot plot showing the expression level of bivalent genes lose either H3K27me3 or H3K4me3 in OA vs Normal (up) and OA-Damaged vs OA-Intact (down).
735 736	(K) Box/Violin plot showing the expression changes of bivalent genes lose either H3K27me3 or H3K4me3 in OA vs Normal (left) and OA-Damaged vs OA-Intact (right).
737 738	(L) Examples of bivalent genes which lose H3K27me3 and gain expression during the progression of OA.
739	
740	Figure 4. Inflammation induced H3K27 demethylase expression in OA chondrocytes.
741 742 743	(A) The RNA expression level of H3K27me3 methylases and demethylases in paired control and IL-1β treated human chondrocytes from OA patients (n=3 for EZH1, n=5 for others). Data were analyzed by two-tailed ratio paired t test
744	(B) Immunofluorescence for KDM6B in human normal and $OA$ cartilage
/	(B) minimulo resolute for reparted in numan normal and OA cartilage.

745 746	(C) Quantification of KDM6B-positive cells in human normal (n=3) and OA (n=9) samples. Data were analyzed by two-tailed unpaired t test and are shown as means ± SD.
747 748 749	(D) The RNA expression level of KDM6B during a time course of IL-1 $\beta$ addition and removal. The same sample was measured repeatedly (n=3). Data were analyzed by ordinary one-way ANOVA followed by Tukey's multiple comparisons test and are shown as means $\pm$ SD.
750 751	(E) H&E staining for synovium and immunofluorescence for KDM6B in rat ACLT- DMM OA models.
752 753 754	(F) Quantification of KDM6B-positive cells in rat control (n=3) and OA (n=3) samples. Data were analyzed by ordinary one-way ANOVA followed by Tukey's multiple comparisons test and are shown as means ± SD. **P < 0.01, ***P < 0.001.
755	
756 757	Figure 5. Demethylase inhibitor rescued inflammation induced H3K27me3 loss and abnormal gene expression.
758 759	(A) Tag density of H3K27me3 across the gene bodies (+/-5kb) genome-wide in human OA chondrocytes during a time course of IL-1β addition and removal.
760 761	(B) Tag density of H3K27me3 across the gene bodies (+/-5kb) genome-wide in human OA chondrocytes treated with IL-1β and GSK-J4 (GJ4).
762 763	(C) Venn diagram of genes which lose H3K27me3 upon IL-1β treatment and restored H3K27me3 by GSK-J4 and genes loss H3K27me3 in OA samples.
764 765	(D) H3K27me3 tag density of the overlapped 569 genes (left) and the other 3092 genes (right) in Fig 3C.
766 767	(E) Examples of H3K27me3 distributions around genes which lose H3K27me3 upon IL-1β treatment and restored H3K27me3 by GSK-J4.
768 769 770 771	(F) Relative expression of genes which lose H3K27me3 upon IL-1β treatment and restored H3K27me3 by GSK-J4. The same sample was measured repeatedly (n=3). Data were analyzed by ordinary one-way ANOVA and are shown as means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
772 773 774	Figure 6. Working model: Inflammation induced epigenetic activation of bivalent genes in osteoarthritic cartilage
775 776 777 778 779 780 781 782 783 783 784	During the osteogenesis of growth plate cartilage, hypertrophy related genes were occupied by both H3K27me3 and H3K4me3 due to the need for rapid activation. However, in its homologous articular chondrocytes, hypertrophic genes remained in a bivalent state. In normal conditions, these bivalent genes maintain transcriptional inhibition; In OA, inflammatory cytokines such as IL-1β induce the expression of H3K27me3 demethylase KDM6B to remove H3K27me3 thus facilize the expression of hypertrophic genes, which promote the degradation of cartilage matrix and leads to OA.
785	Expanded View Figure legends

#### 786 Figure EV1. Histone modification profiling of each normal and OA sample.

- (A) Safranin O-Fast Green staining of human femoral condylar cartilage used for histone
   modification profiling.
- (B) Tag density of each histone mark across the gene bodies (+/-5kb) in each Normal and OA samples.
- (C) Genome-wide peak distribution of each modification in each sample. The numbers of peaks
   in promoter, gene body, enhancer, 10kb nearby gene body, and intergenic regions are
   shown.
- (D) Correlation map of each sample for the four histone marks.

#### 795 Figure EV2. Differences of H3K4me3 and H3K27me3 in normal and OA.

- (A) Venn diagram of genes which lose H3K4me3 in OA vs. Normal and OA-Damaged vs. OA Intact.
- (B) Tag density and heatmap of H3K4me3 across the gene bodies (+/-5kb) of genes which loss
   H3K4me3 in OA vs. Normal, OA-Damaged vs. OA-Intact and both.
- (C) Chromosome distribution of up-regulated H3K4me3 peaks outside genes in OA vs. Normal
   and Dam vs. Int respectively.
- (D) Chromosome distribution of up-regulated H3K27me3 peaks outside genes in OA vs.
   Normal and Dam vs. Int respectively.
- **Figure EV3. Correlation map of each sample for the four histone marks.**

#### **Figure EV4. ChromHMM analysis of human and mice datasets.**

- (A) Enrichment scores for chromatin states in genomic features for 3 normal samples. The first column shows the genome-wide percentage of occupancy for each state. Subsequent
  columns show enrichments for CpG islands, Refseq annotated exons, genes, transcription
  ends sites (TES), transcription start sites (TSS) and TSS + -2 kb regions. Each column is
  colored from 0 (white) to its maximum value (blue).
- (B) Heatmap showing the state agreement between Normal, OA, OA-Int and OA-Dam subsets.
- (C) Chromatin state definitions (emission probabilities) of a 12-state ChromHMM model based
   on the mouse PC/HC data sets.
- (D) The count of genomic bins in each state in mouse PC/HC data sets. (E) State transitions
   from PC to HC.

## Figure EV5. The expression of H3K27 methylation regulators in RNA-seq data from 4 groups.

- 818
- 819
- 820 Table EV1. Quality control of CUT&Tag libraries.
- 821 **Table EV2. Quality control of RNA-seq.**
- Table EV3. Bivalent genes in mouse proliferating chondrocytes that lost H3K27me3 in
   hypertrophic chondrocytes.

#### Figure 1 | Histone modification profiling of normal and OA chondrocytes.



#### Figure 2 | Correlation between histone modification and differential gene expression.



С

an



#### Figure 3 | H3K27me3 loss in bivalent promoters up-regulate gene expression in OA.





[0 - 5.53]

[0 - 5.53]

[0 - 5.53]

[0 - 5.9

1.08

) - 1.08

0 - 1.081

0 - 1.081

ADAMTS2

XR\_941311.2

RNAseq

Gene

#### Figure 4 | Inflammation induced H3K27 demethylase expression in OA chondrocytes.



### Figure 5 | Demethylase inhibitor rescued inflammation induced H3K27me3 loss and abnormal gene expression





0.001

0.000

1,10 11-10+GJA

CHIN





## Figure 6. Working model: Inflammation induced epigenetic activation of bivalent genes in osteoarthritic cartilage

medRxiv preprint doi: https://doi.org/10.1101/2023.04.13.23288509; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **Normal** All rights reserved. No reuse allowed without permission.



#### Figure EV1. Histone modification profiling of each normal and OA sample

A medRxiv preprint doi: https://doi.org/10.1101/2023.04.13.23288509: this version posted April 20. 2923. The copyright holder for this preprint (which was horcentred by peer review) is the author of the author of























#### Figure EV2. Differences of H3K4me3 and H3K27me3 in normal and OA

medRxiv preprint doi: https://doi.org/10.1101/2023.04.13.23288509; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reus callowed without permission. Normal OA-Int OA-Dam



#### Figure EV3. Correlation map of each sample for the four histone marks

medRxiv preprint doi: https://doi.org/10.1101/2023.04.13.23288509; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

-1



-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8

#### H3K9me3





#### H3K27ac

	N30	018	N21	017	N22	015	OA2-Dan	OA2-Int	028	OA1-Int	OA1-Dan
N30	1	0.47	0.12	0.27	0.14	0.26	0.29	0.32	0.44	0.4	0.42
018	0.47	1	0.1	0.28	0.11	0.24	0.24	0.24	0.33	0.32	0.35
N21	0.12	0.1	1	0.44	0.53	0.47	0.35	0.4	0.35	0.44	0.38
017	0.27	0.28	0.44	1	0.54	0.56	0.46	0.46	0.46	0.54	0.54
N22	0.14	0.11	0.53	0.54	1	0.63	0.46	0.51	0.44	0.56	0.47
O15	0.26	0.24	0.47	0.56	0.63	1	0.5	0.54	0.52	0.62	0.55
OA2-Dam	0.29	0.24	0.35	0.46	0.46	0.5	1	0.48	0.49	0.56	0.56
OA2-Int	0.32	0.24	0.4	0.46	0.51	0.54	0.48	1	0.53	0.6	0.53
O28	0.44	0.33	0.35	0.46	0.44	0.52	0.49	0.53	1	0.64	0.6
OA1-Int	0.4	0.32	0.44	0.54	0.56	0.62	0.56	0.6	0.64	1	0.69
OA1-Dam	0.42	0.35	0.38	0.54	0.47	0.55	0.56	0.53	0.6	0.69	1
-1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8								8 1			

#### Figure EV4. ChromHMM analysis of human and mice datasets



#### Figure EV5. The expression of H3K27 methylation regulators in RNA-seq data from 4 groups

